BioCentury | Nov 11, 2020
Emerging Company Profile

CatalYm: opening up tumors to immune cells

...academic founders and collaborators discovered that GDF15 inhibits LFA-1 activation on immune cells. This prevents LFA-1...
...turn prevents the trafficking of immune cells into the tumor microenvironment.Rüdiger added that blocking the LFA-1/ICAM-1...
...Growth differentiation factor 15GFRAL – GDNF family receptor alpha likeICAM-1 (CD54) – Intercellular adhesion molecule-1LFA-1 (CD11a-CD18)PD-1...
BioCentury | Aug 28, 2020
Deals

BARDA enlisting start-ups in fight against COVID-19 via JLABS collaboration

...a small molecule activator of VLA-4 and CD11a-CD18...
BioCentury | May 25, 2018
Clinical News

Bavarian Nordic's ProstVac misses OS endpoint in Phase III for CRPC

Bavarian Nordic A/S (CSE:BAVA) said ProstVac rilimogene galvacirepvec alone and in combination with GM-CSF both missed the primary endpoint of improving overall survival (OS) vs. placebo in the Phase III PROSPECT trial to treat metastatic...
BioCentury | Sep 15, 2017
Financial News

Bavarian Nordic plummets on Phase III CRPC failure of ProstVac

Bavarian Nordic A/S (CSE:BAVA) sank DKK213.50 (48%) to DKK230, losing DKK6.8 billion ($1.1 billion) in market cap, on Friday after an IDMC recommended discontinuing for futility the Phase III PROSPECT trial of ProstVac rilimogene galvacirepvec...
BioCentury | Sep 15, 2017
Clinical News

IDMC recommends discontinuation of Phase III CRPC of ProstVac

Bavarian Nordic A/S (CSE:BAVA) said an IDMC recommended discontinuing for futility the Phase III PROSPECT trial of ProstVac rilimogene galvacirepvec to treat metastatic castration-resistant prostate cancer (CRPC) based on a preplanned interim analysis. The primary...
BioCentury | Sep 14, 2017
Clinical News

IDMC recommends discontinuation of Phase III CRPC trial of ProstVac

Bavarian Nordic A/S (CSE:BAVA) said an IDMC recommended discontinuing for futility the Phase III PROSPECT trial of ProstVac rilimogene galvacirepvec to treat metastatic castration-resistant prostate cancer based on a preplanned interim analysis. The primary endpoint...
BioCentury | Jun 7, 2017
Distillery Therapeutics

Cardiovascular

INDICATION: Thrombosis Mouse studies suggest inhibiting the MAC-1 - GP1BA interaction could help treat thrombosis. In a mouse model of microvascular thrombosis, knockout of MAC-1 decreased platelet accumulation in arterioles compared with normal MAC-1 expression. In...
BioCentury | May 24, 2017
Distillery Techniques

Biomarkers

TECHNOLOGY: SNPs SNPs on six genomic loci could help predict the risk of primary biliary cholangitis. Genome-wide association studies in 2,029 PBC patients and 6,163 healthy volunteers from the Han Chinese population identified independent associations...
BioCentury | May 12, 2017
Strategy

Vertical vision

...is an eye drop formulation of a small molecule integrin beta(2) (LFA-1; MAC-1; CD18) antagonist. LFA-1...
BioCentury | May 1, 2017
Company News

Shire, Parion in deal for ENaC inhibitor for dry eye

...$176.47 on NASDAQ. Jaime De Leon Lifitegrast P-321 ophthalmic solution SAR 1118 SHP606 Xiidra Parion Sciences Inc. Shire plc Epithelial sodium channel (ENaC) Integrin beta(2) (LFA-1...
Items per page:
1 - 10 of 225